|
HLA-DRB1
|
0.370 |
GeneticVariation
|
phenotype |
BEFREE |
Among amoxicillin- and clavulanate-associated cases of European ancestry, rs2476601 doubled the risk for DILI among those with the HLA risk alleles A*02:01 and DRB1*15:01.
|
30664875 |
2019 |
|
HLA-DRB1
|
0.370 |
Biomarker
|
phenotype |
BEFREE |
Similar percentages of patients with DILI had HLA-DRB1*03:01 (15%) and HLA-DRB1*04:01 (9%) as controls (12% and 9%, respectively).
|
27311619 |
2017 |
|
HLA-DRB1
|
0.370 |
Biomarker
|
phenotype |
BEFREE |
There was a tendency towards higher representation of DRB1*14:01 and DQB1*05:03 in DILI AAB+ compared with DILI AAB- (13.8 vs. 4.0%, P=0.02/Pc=0.5; 13.8 vs. 4.7%, P=0.04/Pc=0.5).
|
27206238 |
2016 |
|
HLA-DRB1
|
0.370 |
Biomarker
|
phenotype |
BEFREE |
Studies of ximelagatran, an oral direct thrombin inhibitor withdrawn because of hepatotoxicity, found associations between HLA-DRB1*07:01 and HLA-DQA1*02:01 and ximelagatran DILI.
|
24777842 |
2015 |
|
HLA-DRB1
|
0.370 |
GeneticVariation
|
phenotype |
BEFREE |
The phenotype frequencies of B*1801 (P/Pc = 0.015/0.42, OR 5.2) and DRB1*0301-DQB1*0201 (P/Pc = 0.0026/0.07, OR 15) were increased in AC DILI cases with delayed onset compared to those corresponding to patients without delayed onset, while the opposite applied to DRB1*1302-DQB1*0604 (P/Pc = 0.005/0.13, OR 0.07).
|
23874514 |
2013 |
|
HLA-DRB1
|
0.370 |
GeneticVariation
|
phenotype |
BEFREE |
The strongest effect was with an HLA class II SNP (rs9274407, P=4.8×10(-14)), which correlated with rs3135388, a tag SNP of HLA-DRB1*1501-DQB1*0602 that was previously associated with AC-DILI.
|
21570397 |
2011 |
|
HLA-DRB1
|
0.370 |
Biomarker
|
phenotype |
CTD_human |
The strongest effect was with an HLA class II SNP (rs9274407, P=4.8×10(-14)), which correlated with rs3135388, a tag SNP of HLA-DRB1*1501-DQB1*0602 that was previously associated with AC-DILI.
|
21570397 |
2011 |
|
HLA-DRB1
|
0.370 |
Biomarker
|
phenotype |
BEFREE |
In order to address this problem we have investigated the role of HLA class II DRB1 and DQB1 in 61 cases of co-amoxiclav DILI as part of a UK-wide multicentre study.
|
20800921 |
2010 |